Home › Research › Treatments
Lecanemab autorizado para tratamiento del Alzhéimer en pacientes que tienen una o ninguna copia de ApoE4: una reacción adversa grave limita su uso
Mercedes Sanz. Panorama actual del medicamento, 2025-02-25
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
La Agencia Europea de Medicamentos (EMA), tras realizar su comité CHMP una nueva evaluación de su dictamen inicial negativo en julio 2024, ha recomendado que se otorgue una autorización de comercialización limitada a pacientes de Alzheimer, que tienen una o ninguna copia de ApoE4, una determinada forma del gen de la proteína apolipoproteína E. Esta población tiene menos probabilidades de experimentar anomalías de imagen relacionadas con el amiloide (ARIA), una reacción adversa grave conocida, que implica edema (hinchazón) y posibles hemorragias cerebrales.
What this study adds
Evidence grade: Low
European regulators recommended a limited marketing authorization for lecanemab only in Alzheimer's patients who have one or no copies of the ApoE4 gene. This population is less likely to experience ARIA, a serious adverse reaction involving brain swelling and possible bleeding, which limits the drug's use.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sanz, M. (2025). Lecanemab autorizado para tratamiento del Alzhéimer en pacientes que tienen una o ninguna copia de ApoE4: una reacción adversa grave limita su uso. Panorama actual del medicamento. https://doi.org/10.63105/pam8
Vancouver
Sanz M. Lecanemab autorizado para tratamiento del Alzhéimer en pacientes que tienen una o ninguna copia de ApoE4: una reacción adversa grave limita su uso. Panorama actual del medicamento. 2025. doi:10.63105/pam8.
BibTeX
@article{sanz2025-d2104574,
author = {Sanz, Mercedes},
title = {{Lecanemab autorizado para tratamiento del Alzhéimer en pacientes que tienen una o ninguna copia de ApoE4: una reacción adversa grave limita su uso}},
journal = {Panorama actual del medicamento},
year = {2025},
doi = {10.63105/pam8},
url = {https://doi.org/10.63105/pam8}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- La Agencia Europea de Medicamentos (EMA), tras realizar su comité CHMP una nueva evaluación de su dictamen inicial negativo en julio 2024, ha recomendado que se otorgue una autorización de comercialización limitada a pacientes de Alzheimer, que tienen una o ninguna copia de ApoE4, una determinada forma del gen de la proteína apolipoproteína E.
- Esta población tiene menos probabilidades de experimentar anomalías de imagen relacionadas con el amiloide (ARIA), una reacción adversa grave conocida, que implica edema (hinchazón) y posibles hemorragias cerebrales.
Why it matters
European regulators recommended a limited marketing authorization for lecanemab only in Alzheimer's patients who have one or no copies of the ApoE4 gene. This population is less likely to experience ARIA, a serious adverse reaction involving brain swelling and possible bleeding, which limits the drug's use.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 27/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 25 of the 93 points we could judge it on, which is 27 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Panorama actual del medicamento) |
| Journal's citation record | 0 / 4 | Panorama actual del medicamento: journal h-index 4 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Mercedes Sanz holds only 4 work(s), too few to judge a track record — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 25 / 93 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 25 of the 93 points we could judge it on is 27 out of 100. |
| Total | 27 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.